StockIQpro
NASDAQ:CRBP

Corbus Pharmaceuticals Holdings, Inc.

Track all markets on TradingView
Track all markets on TradingView

Corbus Pharmaceuticals Holdings, Inc. reported net income of −$78.5M in fiscal 2025. Free cash flow was −$64.5M, and the diluted share count rose 22.0%.Summary generated from Corbus Pharmaceuticals Holdings, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−54.2%
Debt / equityn/a
Free cash flow−$64.5M
FCF marginn/a
Share count change+22.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue10n/an/an/a
Operating income−56−40−45−49−85
Net income−46−42−45−40−79
Free cash flow−48−38−36−42−64

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations